TY - JOUR
T1 - Safety and Efficacy of Cangrelor in Acute Coronary Syndromes
T2 - A Systematic Review and Network Meta-Analysis
AU - Mostafa, Mostafa Reda
AU - Eid, Mohamed Magdi
AU - Awad, Ahmed K.
AU - Takla, Andrew
AU - Hassan, Abdul Rhman
AU - Katamesh, Basant E.
AU - AlBarakat, Majd M.
AU - Ziada, Abdul Rhman
AU - Mohamed, Sarah
AU - Al-Azizi, Karim M.
AU - Goldsweig, Andrew M.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2024/1
Y1 - 2024/1
N2 - Introduction: Cangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes. Methods: This meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion. Results: The analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion. Conclusion: Cangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.
AB - Introduction: Cangrelor is a potent intravenous non-thienopyridine P2Y12 inhibitor. We conducted a network meta-analysis to study the efficacy and safety of cangrelor as compared with the oral P2Y12 inhibition, clopidogrel, or placebo in acute coronary syndromes. Methods: This meta-analysis followed the Cochrane collaboration guidelines and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) protocols. Outcomes of interest included all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, major bleeding, minor bleeding, and the need for blood transfusion. Results: The analysis was comprised of 6 studies including 26,444 patients treated with cangrelor, clopidogrel, or placebo. There were no statistically significant differences in the incidence of all-cause mortality, myocardial infarction, stent thrombosis, target vessel revascularization, or major bleeding. Cangrelor was associated with a higher risk of minor bleeding than clopidogrel or placebo, with no difference in requiring blood transfusion. Conclusion: Cangrelor has comparable outcomes to clopidogrel in patients with acute coronary syndromes and can be used as a reliable alternative in this population.
UR - http://www.scopus.com/inward/record.url?scp=85177601281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177601281&partnerID=8YFLogxK
U2 - 10.1007/s40256-023-00616-2
DO - 10.1007/s40256-023-00616-2
M3 - Review article
C2 - 37995040
AN - SCOPUS:85177601281
SN - 1175-3277
VL - 24
SP - 71
EP - 81
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 1
ER -